q,Fcn@ ?1 1 aD+#`D_ 7l/OiERy9O; Wf4et = b/@K2 gP&8BC(Zf gNOoOco2uOuO (u:+ }BH(&}F}B ]M dOpob!p[ 0:D! BgM/*&gr*BgvB/MVOB[ Eyoyy i&[v?_i 132`2O33^m3 J;[N;S&uViSuJJ -bBILSIbCsI zspRso~; A8ttD!tt$. oWY =p(vI[( nY (`J Rix `!Oe3 X3XW|qbq =3 o`t( qBPXx tkV kH^@^9V^D Y+ lq/, JPuZL -}L.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/&RP,mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.